Universe Pharmaceuticals INC (NASDAQ:UPC – Get Free Report) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 239,483 shares, an increase of 1,955.8% from the June 15th total of 11,649 shares. Based on an average daily volume of 7,749,497 shares, the days-to-cover ratio is currently 0.0 days. Currently, 99.8% of the shares of the stock are sold short.
Universe Pharmaceuticals Price Performance
Shares of Universe Pharmaceuticals stock traded down $0.07 on Friday, reaching $5.27. The company had a trading volume of 308,161 shares, compared to its average volume of 4,370,532. The firm’s 50 day moving average price is $3.69 and its two-hundred day moving average price is $3.49. Universe Pharmaceuticals has a 52-week low of $2.00 and a 52-week high of $17.96.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings upgraded Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.
Universe Pharmaceuticals Company Profile
Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.
The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.
Featured Articles
- Five stocks we like better than Universe Pharmaceuticals
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Universe Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Universe Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
